News about Global Pharma

Novartis Gets FDA Accelerated Approval for Vanrafia

Vanrafia was granted accelerated approval based on a prespecified interim analysis of the Phase III ALIGN study measuring the reduction of proteinuria at 36 weeks compared to placebo1. It has not been established whether Vanrafia slows kidney function decline in patients with IgAN.

Global Pharma | 03/04/2025 | By Aishwarya |  383

Lupin Acquires Renascience to Expand its Footprint in United Kingdom

With this acquisition, Lupin Healthcare (UK) gains full ownership of Renascience which, going forward, will trade as its subsidiary.

Global Pharma | 03/04/2025 | By Aishwarya |  402

Syntegon Plans to Relocate and Expand Business Growth at New Sites

The activities of the Pharma Solid business unit located in Waiblingen will move to a dedicated pharma site in neighboring Fellbach in the second half of 2025.

Global Pharma | 03/04/2025 | By Aishwarya |  542

Alembic Pharmaceuticals Secures USFDA Nod for Key GERD Injection Drug

The drug is a therapeutic equivalent to Protonix I.V., originally developed by Wyeth Pharmaceuticals, and is used to manage gastroesophageal reflux disease (GERD), erosive esophagitis, and certain rare hypersecretion conditions like Zollinger-Ellison Syndrome in adults.

Global Pharma | 02/04/2025 | By Aishwarya |  294

Freudenberg Achieves Stable Growth in 2024 with Increased Profit Margins

. Operating profit grew by about 4.7 percent, reaching EUR 1,132.4 million, up from EUR 1,081.6 million last year.

Global Pharma | 02/04/2025 | By Aishwarya |  435

Azenta Launches Automated Plate Seal Remover to Boost Lab Performance

Designed for unattended operation, the Automated Plate Seal Remover is an ideal solution for life science labs that routinely remove microplate seals.

Global Pharma | 02/04/2025 | By Aishwarya |  282

Strides Pharma Gets Recognition in S&P Global Sustainability Yearbook 2025

This recognition reflects Strides progress in integrating ESG principles across its operations.

Global Pharma | 02/04/2025 | By Aishwarya |  696

Gennova Collaborates with CEPI to Advances AI-Enhanced saRNA Vaccine for Nipah Virus

Gennova Biopharmaceuticals, a subsidiary of Emcure Pharmaceuticals, partners with Coalition for Epidemic Preparedness Innovations (CEPI) and Houston Methodist to develop an AI-enhanced saRNA vaccine for the deadly Nipah virus, securing up to USD 13.38 million for accelerated research and trials in India.

Global Pharma | 01/04/2025 | By Manvi |  421

Akums Becomes First Indian CDMO to Receive DCGI Approval for Innovative Glaucoma Treatment

Glaucoma ranks as the second leading cause of irreversible but preventable blindness worldwide, with India contributing to 23.5 percent of the global burden.

Global Pharma | 01/04/2025 | By Abha |  563

Orna Therapeutics Appoints Joseph Bolen, Ph.D., as Chief Executive Officer

Orna Therapeutics announced the appointment of Joseph Bolen, Ph.D., as Chief Executive Officer. Dr. Bolen most recently served as Orna's Chief Scientific Officer (CSO) and succeeds Amit Munshi who is stepping aside for personal reasons.

Global Pharma | 31/03/2025 | By Manvi |  192